Health1 min read

Pill to treat pancreatic cancer hailed as ‘biggest breakthrough in decades’

By · Via The Guardian Science · Published by Everything Blog

In short

The clinical trial tracked 61 patients with metastasized pancreatic cancer over an average duration of 18 months. Beyond stopping disease progression, the pill shrank or eliminated tumours in over 60% of participants, leaving roughly 8% with no detectable tumours on CT scans. Survival outcomes improved drastically, with 76.6% alive at one year compared to typical chemotherapy rates of 40% to 45%. Researchers now plan extended trials to confirm whether these remissions can become permanent.

Key points

  • The medication functions as a KRAS inhibitor by disabling the specific mutations driving…: The medication functions as a KRAS inhibitor by disabling the specific mutations driving pancreatic cancer growth.
  • Scans showed that tumours became entirely undetectable in approximately one out of every…: Scans showed that tumours became entirely undetectable in approximately one out of every 12 treated patients.
  • Medical experts are planning further studies to evaluate the therapy for wider health sys…: Medical experts are planning further studies to evaluate the therapy for wider health system adoption and long-term remission.

Sources checked by our analysis pipeline: 1

A pill that can shrink and potentially eliminate pancreas tumours is being hailed as the biggest breakthrough treatment for the cancer in decades.

In one in 12 of the patients given the drug, daraxonrasib, during a trial, the cancer became undetectable, and the tumours stopped growing in almost all of the 61 patients. The trial participants had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.

Though doctors have said the pill cannot yet be considered a cure, and they do not know how long it can keep the disease at bay, they have said it is encouraging news because it appears it will offer patients more time, even if it does not cause full remission.

Half of all people diagnosed with pancreatic cancer die within three months, and only about 3% of patients survive for five years when the disease spreads to other organs. It has the lowest survival rate of all common cancers in the UK.

Patients were followed for a year and a half during the trial on average and…

Health